145 related articles for article (PubMed ID: 38640587)
1. M
Fu L; Luo Y; Niu L; Lin Y; Chen X; Zhang J; Tang W; Chen Y; Jiao Y
Bioorg Med Chem; 2024 May; 105():117728. PubMed ID: 38640587
[TBL] [Abstract][Full Text] [Related]
2. Positive allosteric modulation of M
Yohn SE; Conn PJ
Neuropharmacology; 2018 Jul; 136(Pt C):438-448. PubMed ID: 28893562
[TBL] [Abstract][Full Text] [Related]
3. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.
Conn PJ; Jones CK; Lindsley CW
Trends Pharmacol Sci; 2009 Mar; 30(3):148-55. PubMed ID: 19201489
[TBL] [Abstract][Full Text] [Related]
4. Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders.
Teal LB; Gould RW; Felts AS; Jones CK
Adv Pharmacol; 2019; 86():153-196. PubMed ID: 31378251
[TBL] [Abstract][Full Text] [Related]
5. Involvement of Striatal Cholinergic Interneurons and M1 and M4 Muscarinic Receptors in Motor Symptoms of Parkinson's Disease.
Ztaou S; Maurice N; Camon J; Guiraudie-Capraz G; Kerkerian-Le Goff L; Beurrier C; Liberge M; Amalric M
J Neurosci; 2016 Aug; 36(35):9161-72. PubMed ID: 27581457
[TBL] [Abstract][Full Text] [Related]
6. Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic.
Yohn SE; Weiden PJ; Felder CC; Stahl SM
Trends Pharmacol Sci; 2022 Dec; 43(12):1098-1112. PubMed ID: 36273943
[TBL] [Abstract][Full Text] [Related]
7. Discovery and Development of Muscarinic Acetylcholine M
Takai K; Enomoto T
Chem Pharm Bull (Tokyo); 2018; 66(1):37-44. PubMed ID: 29311510
[TBL] [Abstract][Full Text] [Related]
8. Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M
Gould RW; Grannan MD; Gunter BW; Ball J; Bubser M; Bridges TM; Wess J; Wood MW; Brandon NJ; Duggan ME; Niswender CM; Lindsley CW; Conn PJ; Jones CK
Neuropharmacology; 2018 Jan; 128():492-502. PubMed ID: 28729220
[TBL] [Abstract][Full Text] [Related]
9. Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats.
Brugnoli A; Pisanò CA; Morari M
Neurobiol Dis; 2020 Oct; 144():105044. PubMed ID: 32798726
[TBL] [Abstract][Full Text] [Related]
10. Structural Features of Iperoxo-BQCA Muscarinic Acetylcholine Receptor Hybrid Ligands Determining Subtype Selectivity and Efficacy.
Wakeham MCL; Davie BJ; Chalmers DK; Christopoulos A; Capuano B; Valant C; Scammells PJ
ACS Chem Neurosci; 2022 Jan; 13(1):97-111. PubMed ID: 34905693
[TBL] [Abstract][Full Text] [Related]
11. Identification of N-substituted 8-azatetrahydroquinolone derivatives as selective and orally active M(1) and M(4) muscarinic acetylcholine receptors agonists.
Takai K; Inoue Y; Konishi Y; Suwa A; Uruno Y; Matsuda H; Nakako T; Sakai M; Nishikawa H; Hashimoto G; Enomoto T; Kitamura A; Uematsu Y; Kiyoshi A; Sumiyoshi T
Bioorg Med Chem Lett; 2013 Aug; 23(16):4644-7. PubMed ID: 23816371
[TBL] [Abstract][Full Text] [Related]
12. [Muscarinic M1 and/or M4 receptor agonists as potential novel treatments for psychoses].
Spoelstra SK; Visser L; Knegtering H
Tijdschr Psychiatr; 2023; 65(9):555-562. PubMed ID: 37947466
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of TAK-071, a muscarinic M
Kurimoto E; Yamada R; Hirakawa T; Kimura H
Neurosci Lett; 2021 Nov; 764():136240. PubMed ID: 34509568
[TBL] [Abstract][Full Text] [Related]
14. Muscarinic acetylcholine receptors as CNS drug targets.
Langmead CJ; Watson J; Reavill C
Pharmacol Ther; 2008 Feb; 117(2):232-43. PubMed ID: 18082893
[TBL] [Abstract][Full Text] [Related]
15. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats.
Jones CK; Brady AE; Davis AA; Xiang Z; Bubser M; Tantawy MN; Kane AS; Bridges TM; Kennedy JP; Bradley SR; Peterson TE; Ansari MS; Baldwin RM; Kessler RM; Deutch AY; Lah JJ; Levey AI; Lindsley CW; Conn PJ
J Neurosci; 2008 Oct; 28(41):10422-33. PubMed ID: 18842902
[TBL] [Abstract][Full Text] [Related]
16. Novel M(1) allosteric ligands: a patent review.
Kuduk SD; Beshore DC
Expert Opin Ther Pat; 2012 Dec; 22(12):1385-98. PubMed ID: 23092292
[TBL] [Abstract][Full Text] [Related]
17. Discovery of dihydroquinazolinone derivatives as potent, selective, and CNS-penetrant M(1) and M(4) muscarinic acetylcholine receptors agonists.
Uruno Y; Konishi Y; Suwa A; Takai K; Tojo K; Nakako T; Sakai M; Enomoto T; Matsuda H; Kitamura A; Sumiyoshi T
Bioorg Med Chem Lett; 2015 Nov; 25(22):5357-61. PubMed ID: 26428869
[TBL] [Abstract][Full Text] [Related]
18. Biased Profile of Xanomeline at the Recombinant Human M
McDonald JK; van der Westhuizen ET; Pham V; Thompson G; Felder CC; Paul SM; Thal DM; Christopoulos A; Valant C
ACS Chem Neurosci; 2022 Apr; 13(8):1206-1218. PubMed ID: 35380782
[TBL] [Abstract][Full Text] [Related]
19. Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases.
Felder CC; Goldsmith PJ; Jackson K; Sanger HE; Evans DA; Mogg AJ; Broad LM
Neuropharmacology; 2018 Jul; 136(Pt C):449-458. PubMed ID: 29374561
[TBL] [Abstract][Full Text] [Related]
20. Muscarinic M1 and M4 receptors: Hypothesis driven drug development for schizophrenia.
Dean B; Scarr E
Psychiatry Res; 2020 Jun; 288():112989. PubMed ID: 32315882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
